Campbell Soup (CPB) 24Q1 Update

Campbell Soup Company (CPB) reported 24Q1 diluted GAAP EPS of $0.78, below last year’s $0.99 and also below my estimate of $0.82.  Non-GAAP EPS was $0.91, below last year’s $1.02, but above my estimate of $0.85.  Net sales were $2.52 billion, 2.2% below 23Q1 and below my estimate.

Results were in line with management’s expectations, as the company was up against a tough prior year comparison (when sales were up 15% due to price increases, brand strength and continued recovery in supply).  Sales in the Meals & Beverages segment decreased 4%, with sales volume down 6%, partially offset by net price realization of 2%.  M&B operating earnings declined 13%.  Sales in the Snacks segment declined 1%, as a 4% decrease in volume and 2% decrease due to a divestiture were mostly offset by net price realization of 5%.  Snacks operating earnings increased by 5%.  Management said that the holiday season is off to a great start.  It expects to build sales momentum through the rest of the fiscal year.  Consequently, it expressed confidence in its reaffirmed fiscal 2024 guidance.

That guidance anticipates net sales growth of ‑0.5% to +1.5% (including a 0.5% decline due to last year’s sale of the Emerald nuts business), organic net sales growth of 0% to 2%, adjusted EBIT growth of 3% to 5% and adjusted EPS growth of 3% to 5% (or $3.09 to $3.15). Management’s guidance does not include the potential impact of the Sovos Brands acquisition, which is now expected to close sometime during calendar 2024, with a mid-2024 target (i.e. near the end of the fiscal year). Updated for 24Q1 results, I have reduced my fiscal 2024 GAAP EPS estimate to $2.74 (from $2.82) and my non-GAAP estimate to $3.00 (from $3.02).  As a reminder, my estimates are below management’s guidance of $3.09-$3.15 because they include the estimated impact of the Sovos Brands acquisition.  For fiscal 2025, my GAAP EPS estimate of $2.65 and non-GAAP EPS estimate of $2.95 are unchanged.  Since my last report, Campbell’s stock has risen 6%, compared with the S&P 500’s 12.0% gain and peers’ 8.4% gain.  In my view, Campbell’s performance remains on track and so I am maintaining my 12-month price target of $50 and my performance rating of “1” (Buy).  The revised target price represents a potential return of nearly 20%, including the stock’s 3.4% dividend yield.

This is a summary of my recent report on Campbell Soup Company (CPB). To obtain a copy of the full report, please reach out to me using the contact information provided below.

December 11, 2023 (The report’s publish date is December 8, 2023.)

Stephen P. Percoco
Lark Research
839 Dewitt Street
Linden, New Jersey 07036
(908) 975-0250
admin@larkresearch.com

© 2015-2024 by Stephen P. Percoco, Lark Research.   All rights reserved.

This blog post (as with all posts on this website) represents the opinion of Lark Research based upon its own independent research and supporting information obtained from various sources. Although Lark Research believes these sources to be reliable, it has not independently confirmed their accuracy. Consequently, this blog post may contain errors and omissions. Furthermore, this blog post is a summary of a recent report published on this subject and that report provides a more complete discussion and assessment of the risks and opportunities of any investment securities discussed herein. No representation or warranty is expressed or implied by the publication of this blog post. This blog post is for informational purposes only and shall not be construed as investment advice that meets the specific needs of any investor. Investors should, in consultation with their financial advisers, determine the suitability of the post’s recommendations, if any, to their own specific circumstances. Lark Research is not registered as an investment adviser with the Securities and Exchange Commission, pursuant to exemptions provided in the Investment Company Act of 1940. This blog post remains the property of Lark Research and may not be reproduced, copied or similarly disseminated, in whole or in part, without its prior written consent.

This entry was posted in Consumer Staples, CPB and tagged . Bookmark the permalink.